



## **Pluristem to Present at Omics Group's 2<sup>nd</sup> International Conference and Exhibition on Cell & Gene Therapy**

HAIFA, Israel October 23, 2013 -- [Pluristem Therapeutics Inc.](#) (NASDAQCM: [PSTI](#)) (TASE:PLTR), a leading developer of placenta-based cell therapies, announced today that Pluristem's VP of Development, Ohad Karnieli PhD will present at [Omics Group's 2nd International Conference and Exhibition on Cell & Gene Therapy](#) in Orlando, Florida on October 25, 2013 at 12:50pm. Dr. Karnieli's presentation will focus on Pluristem's approach on industrialized cell therapy manufacturing.

As previously announced, Pluristem's 3-dimensional cell production is manufactured in its state-of-the-art 40,000 square foot [facility](#).

Omics Group's 2nd International Conference and Exhibition on Cell & Gene Therapy 2013 is an event which brings together a unique and international mix of leading universities and cell therapy institutions making the congress a perfect platform to share experience. It paves a way to gather visionaries through the research talks and presentations and put forward many thought provoking strategies in emerging cell & gene therapies. The conference aims to serve as a catalyst for the advancement in cell & gene therapies by connecting scientists within and across disciplines at conferences held under a single roof that create an environment conducive to information exchange, generation of new ideas and acceleration of applications that benefit society.

### **About Pluristem Therapeutics**

Pluristem Therapeutics Inc. is a leading developer of placenta-based cell therapies. The Company's patented PLX (PLacental eXpanded) cells are a drug delivery platform that releases a cocktail of therapeutic proteins in response to a host of local and systemic inflammatory and ischemic diseases. PLX cells are grown using the company's proprietary 3D micro-environmental technology and are an "off-the-shelf" product that requires no tissue matching prior to administration.

Pluristem has a strong intellectual property position, company-owned GMP certified manufacturing and research facilities, strategic relationships with major research institutions and a seasoned management team. For more information visit [www.pluristem.com](http://www.pluristem.com), the content of which is not part of this press release.

### **Safe Harbor Statement**

This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and federal securities laws. These forward-looking statements and their implications are based on the current expectations of the management of Pluristem only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; we may encounter delays or obstacles in launching and/or successfully completing our clinical trials; our products may not be approved by regulatory agencies, our technology may not be validated as we progress further and our methods may not be accepted by the scientific community; we may be unable to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties may develop with our process; our products may wind up being more expensive than we anticipate; results in the laboratory may not translate to equally good results in real surgical settings; results of preclinical studies may not correlate with the results of human clinical trials; our patents may not be sufficient; our products may harm recipients; changes in legislation; inability to timely develop and introduce new technologies, products and applications; loss of market share and pressure on pricing resulting from competition, which could cause the actual results or performance of Pluristem to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Pluristem undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting Pluristem, reference is made to Pluristem's reports filed from time to time with the Securities and Exchange Commission.

***Contact:***

Pluristem Therapeutics Inc.:

William Prather R.Ph., M.D. Sr. VP Corporate Development

1-303-883-4954

[William.PratherMD@pluristem.com](mailto:William.PratherMD@pluristem.com)

Daya Lettvin

Investor & Media Relations Director

+972-54-674-5580

[daya@pluristem.com](mailto:daya@pluristem.com)